文献速递重症综合管理与镇静镇痛

利用ICURx通用数据模型的无监督聚类分析识别重症监护室药物的药物表型

Pharmacophenotype identification of intensive care unit medications using unsupervised cluster analysis of the ICURx common data model.
PubMed 文献 · Crit Care · 2023-05-02
一句话结论在991例重症成人中,对入ICU前24小时用药记录行无监督聚类,识别出5个患者聚类和6个药物表型,聚类5机械通气时间和ICU住院时间显著更短(p<0.05)。

该回顾性观察性队列研究纳入991例重症成人,基于ICU用药通用数据模型(CDM-ICURx),对入ICU前24小时用药记录采用受限玻尔兹曼机自动特征学习联合层次聚类进行无监督分析,共分析30,550条医嘱,识别出5个患者聚类和6个药物表型。与聚类1和3相比,聚类5机械通气时间和ICU住院时间显著更短(p<0.05),且药物表型1分布更高、表型2分布更低。聚类2疾病严重程度最高、用药方案最复杂,但总体死亡率最低,药物表型6分布相对更高。作者认为这些模式在床旁应用尚需进一步算法开发和临床验证。

要点

  • 回顾性观察性队列纳入991例重症成人,分析入ICU前24小时共30,550条用药医嘱,识别出5个患者聚类和6个药物表型。
  • 与聚类1和3相比,聚类5机械通气时间和ICU住院时间显著更短(p<0.05),药物表型1分布更高、表型2分布更低。
  • 聚类2疾病严重程度最高、用药方案最复杂,但总体死亡率最低,药物表型6分布相对更高。
  • 作者认为将上述模式用于床旁尚需进一步算法开发和临床应用。

适用人群与场景

  • 991例重症成人,分析入ICU前24小时内的用药记录。

研究设计与关键结果

  • 研究类型:回顾性观察性队列研究,样本量991例重症成人。
  • 共分析30,550条用药医嘱,识别出5个患者聚类和6个药物表型;采用受限玻尔兹曼机自动特征学习联合层次聚类,层次凝聚聚类用于识别患者聚类;组间比较采用符号秩检验和Fisher精确检验。
  • 与聚类1和3相比,聚类5机械通气时间和ICU住院时间显著更短(p<0.05);聚类5药物表型1分布更高、药物表型2分布更低。
  • 聚类2疾病严重程度最高、用药方案最复杂,但总体死亡率最低;聚类2药物表型6分布相对更高。

证据类型、等级与局限

  • 证据类型:回顾性观察性队列研究。
  • 局限:作者指出将上述模式应用于床旁尚需进一步算法开发和临床应用。

对床旁实践的改变

  • 作者认为这些患者聚类与用药方案模式在床旁应用尚需进一步算法开发和临床应用,未来可能有助于指导用药相关决策以改善治疗结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Identifying patterns within ICU medication regimens may help artificial intelligence algorithms to better predict patient outcomes; however, machine learning methods incorporating medications require further development, including standardized terminology. The Common Data Model for Intensive Care Unit (ICU) Medications (CDM-ICURx) may provide important infrastructure to clinicians and researchers to support artificial intelligence analysis of medication-related outcomes and healthcare costs. Using an unsupervised cluster analysis approach in combination with this common data model, the objective of this evaluation was to identify novel patterns of medication clusters (termed 'pharmacophenotypes') correlated with ICU adverse events (e.g., fluid overload) and patient-centered outcomes (e.g., mortality).

METHODS: This was a retrospective, observational cohort study of 991 critically ill adults. To identify pharmacophenotypes, unsupervised machine learning analysis with automated feature learning using restricted Boltzmann machine and hierarchical clustering was performed on the medication administration records of each patient during the first 24 h of their ICU stay. Hierarchical agglomerative clustering was applied to identify unique patient clusters. Distributions of medications across pharmacophenotypes were described, and differences among patient clusters were compared using signed rank tests and Fisher's exact tests, as appropriate.

RESULTS: A total of 30,550 medication orders for the 991 patients were analyzed; five unique patient clusters and six unique pharmacophenotypes were identified. For patient outcomes, compared to patients in Clusters 1 and 3, patients in Cluster 5 had a significantly shorter duration of mechanical ventilation and ICU length of stay (p < 0.05); for medications, Cluster 5 had a higher distribution of Pharmacophenotype 1 and a smaller distribution of Pharmacophenotype 2, compared to Clusters 1 and 3. For outcomes, patients in Cluster 2, despite having the highest severity of illness and greatest medication regimen complexity, had the lowest overall mortality; for medications, Cluster 2 also had a comparably higher distribution of Pharmacophenotype 6.

CONCLUSION: The results of this evaluation suggest that patterns among patient clusters and medication regimens may be observed using empiric methods of unsupervised machine learning in combination with a common data model. These results have potential because while phenotyping approaches have been used to classify heterogenous syndromes in critical illness to better define treatment response, the entire medication administration record has not been incorporated in those analyses. Applying knowledge of these patterns at the bedside requires further algorithm development and clinical application but may have the future potential to be leveraged in guiding medication-related decision making to improve treatment outcomes.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Sikora A, Rafiei A, Rad MG, et al. Pharmacophenotype identification of intensive care unit medications using unsupervised cluster analysis of the ICURx common data model. Crit Care. 2023. PMID: 37131200. doi:10.1186/s13054-023-04437-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。